GeoMx® Cancer Transcriptome Atlas
Helping Your Research
The GeoMx® Cancer Transcriptome Atlas (CTA) is designed for comprehensive profiling of tumor biology, the tumor microenvironment, and the immune response. Profile RNA expression of over 1,800 genes simultaneously with spatial resolution from distinct regions of interest with a single tissue section using the GeoMx Digital Spatial Profiler.
The GeoMx CTA is designed to profile all aspects of tumor and tumor microenvironment biology
- Profile the global immune response
- Assess microenvironment immune activity
- Quantify tumor reactivity to the immune response and therapeutic treatments
- Measure clinically-derived gene sets including the 18-gene Tumor Inflammation Signature (TIS) known to be associated with response to PD-1/PD-L1 inhibitor pathway blockade, and the 50-gene Prediction Analysis of Microarray 50 signature (PAM50) known to be associated with breast cancer metastasis.
How it Works
The Cancer Transcriptome Atlas (CTA) spatially profiles targets critical to oncology and immuno-oncology research on the GeoMx Digital Spatial Profiler.
Comprehensive RNA content designed for cancer biology research in any tissue sample
- Coverage of the immune response, tissue microenvironment, tumor biology, and genes from clinically relevant genes sets such as the Tumor Inflammation Signature and PAM50
- Analysis of over 100 pathways to explore tumor biology
Compatible with RNAscope® and antibody morphology markers for tissue imaging
Customizable with up to 60 additional targets of interest
For use with next-generation sequencer (NGS) readout and compatible with DSP Data Center
In The Lab
Spatially resolved transcriptomics and its applications in cancer
Spatially resolved transcriptomics (SRT) offers the promise of understanding cells and their modes of dysfunction in the context of intact tissues. Technologies for SRT have advanced rapidly with a large number being published in recent years.
Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors
In recent years, cancer immunotherapy experienced remarkable developments and it is nowadays considered a promising therapeutic frontier against many types of cancer, especially hematological malignancies. However, in most types of solid tumors, immunotherapy efficacy is modest, partly because of the limited accessibility of lymphocytes to the tumor core.
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma
Synovial sarcoma (SyS) is an aggressive neoplasm driven by the SS18-SSX fusion, and is characterized by low T cell infiltration. Here, we studied the cancer-immune interplay in SyS using an integrative approach that combines single-cell RNA sequencing (scRNA-seq), spatial profiling and genetic and pharmacological perturbations.
Spatial Genomics Summit